Clinical Trial Update: The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Trastuzumab Rezetecan (SHR-A1811) in patients with HER2-low unresectable/metastatic breast cancer with visceral crisis;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab Rezetecan

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis | Phase 2 | Status: RECRUITING